Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1
Completed · Phase 1 · Has a placebo group
Conditions studied: Myotonic Dystrophy, Type 1 (DM1), Myotonic Dystrophy
In brief
Participants in this study will receive two treatments, placebo and ERX-963, on different days in a randomized fashion. The primary purpose of this study is to investigate the safety and tolerability of ERX-963 in participants diagnosed with Myotonic Dystrophy, Type 1 (DM1). The secondary purpose is to evaluate the potential of ERX-963 treatment to reduce excessive daytime sleepiness / hypersomnia and improve cognitive function in DM1 participants compared to placebo treatment.
Key facts
- Study ID
- NCT03959189
- Run by
- Expansion Therapeutics, Inc.
- People needed
- 12
- Starts
- 2019-06-17
- Expected to finish
- 2020-04-30
- Last updated by the study team
- 2021-06-23
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford Neurosciences Health Center — Palo Alto, California, United States
- Sleep Medicine Specialists of South Florida — Miami, Florida, United States
- University of Iowa — Iowa City, Iowa, United States
- The Center for Sleep & Wake Disorders — Chevy Chase, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.